Pemphigus VulgarisRESET-PV-CARTNCT07681388
CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris
A study testing Autologous CD19 CAR-T cells in people with Pemphigus Vulgaris, run by Jinbo Chen at 1 site in China.
Trial summary
This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Pemphigus Vulgaris
- What is being tested?
- Autologous CD19 CAR-T cells
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3 participants
- Where
- 1 siteChina
- Study dates
- 15 Jan 2026to 30 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must meet all of the following criteria:
- Ability to provide written informed consent.
- Age 18 to 70 years at screening, male or female.
- Diagnosis of pemphigus vulgaris confirmed by clinical presentation, histopathology, direct immunofluorescence (DIF), and positive anti-desmoglein 3 and/or anti-desmoglein 1 antibodies.
- Moderate-to-severe disease activity defined as Pemphigus Disease Area Index (PDAI) ≥ 15 at screening.
- Refractory pemphigus vulgaris is defined as inadequate response, disease relapse, or treatment dependence following systemic corticosteroids and rituximab-based therapy for at least 6 months, with persistent disease activity meeting at least one of the following criteria:
Show all 21Show fewer
- Ongoing active disease with the appearance of new erythema, blisters, or erosions;
- Persistently elevated anti-desmoglein 1 or anti-desmoglein 3 antibody titers > 100 U/mL;
- Inability to taper systemic corticosteroids to < 20 mg/day prednisone equivalent (i.e., ≥ 4 tablets/day of standard prednisone dosing).
- Requirement for systemic therapy at screening due to active disease.
- Adequate vascular access for leukapheresis.
- Life expectancy greater than 6 months.
- Participants must have adequate organ function as defined below:
- Hematologic function: absolute neutrophil count ≥ 1.0 × 10⁹/L, platelet count ≥ 50 × 10⁹/L, hemoglobin ≥ 80 g/L.
- Renal function: Creatinine clearance ≥ 40 mL/min.
- Hepatic function: ALT and AST ≤ 2.5 × upper limit of normal; total bilirubin ≤ 1.5 × upper limit of normal.
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% with no clinically significant cardiac dysfunction.
- Pulmonary function: Dyspnea ≤ Grade 1 (CTCAE v5.0) and oxygen saturation (SpO₂) ≥ 92% on room air.
- Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × upper limit of normal, with no clinically significant coagulopathy.
- 9. No evidence of clinically significant active infection at baseline evaluation.
- 10. Reproductive Criteria: Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) test within 48 hours prior to initiation of lymphodepleting chemotherapy. Women of childbearing potential must agree to use effective contraception during study participation and for at least 12 months after CAR-T infusion. Male participants must agree to use effective contraception and avoid sperm donation during study participation and for at least 12 months after infusion.
Who cannot join
- Participants meeting any of the following criteria will be excluded:
- Active uncontrolled infection at screening, requiring systemic antimicrobial therapy. Participants with active tuberculosis, hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis infection will be excluded. Participants with hepatitis B surface antigen and/or hepatitis B core antibody positivity may be eligible only if HBV DNA is below the lower limit of quantification and appropriate antiviral prophylaxis is provided at the investigator's discretion.
- History of other active autoimmune disease requiring systemic immunosuppression.
- Previous treatment with any gene-modified cellular therapy, including CAR-T or CAR-NK therapy.
- Prior allogeneic stem cell or solid organ transplantation.
- Severe or uncontrolled cardiovascular, pulmonary, hepatic, or renal disease that would increase risk associated with lymphodepleting chemotherapy or CAR-T cell infusion.
Show all 14Show fewer
- Use of high-dose systemic corticosteroids (>1 mg/kg/day prednisone equivalent) within 7 days prior to leukapheresis.
- Use of rituximab or other B-cell-targeted biologics within protocol-defined washout period.
- Use of intravenous immunoglobulin, plasma exchange, or other intensive immunomodulatory therapy within 2 weeks prior to leukapheresis.
- Received live vaccine within 8 weeks prior to screening.
- History of malignancy within 5 years prior to enrollment, except adequately treated non-melanoma skin cancer or in situ carcinoma.
- Pregnancy or breastfeeding.
- Known hypersensitivity to any component of lymphodepleting chemotherapy or CAR-T cell product.
- Any condition that, in the investigator's judgment, would compromise patient safety or study integrity.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Xiaoya Du contact
China1 site, 1 recruiting
- Recruiting
Traditional Chinese and Western Medicine Hospital of Wuhan, Wuhan, Hubei
Wuhan, Hubei
Jinbo Chen, MD+PhD, +86 188 2736 3048, chen999jb@163.com
About this study
Official title: A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CD19 CAR-T Cell Therapy in Patients With Moderate-to-Severe Refractory Pemphigus Vulgaris
This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Read the detailed description
This is an investigator-initiated, open-label, single-center, single-arm exploratory interventional study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immune reconstitution, and preliminary clinical efficacy of autologous CD19 CAR-T cell therapy in adult patients with moderate-to-severe refractory pemphigus vulgaris.
Eligible participants are adults with refractory pemphigus vulgaris. After enrollment, participants will undergo leukapheresis for ex vivo manufacturing of autologous CD19 CAR-T cells. After product release, participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide within 2 to 7 days prior to CAR-T infusion.
Participants will receive a single intravenous infusion of autologous CD19 CAR-T cells at a protocol-defined dose (1 X 10^6 CAR-positive T cells per kilogram of body weight). Premedication may be administered at investigator discretion. No comparator group is included.
Participants will be followed for up to 96 weeks after infusion. Safety assessments include monitoring for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections, cytopenias, organ toxicities, and other treatment-emergent adverse events.
Efficacy assessments include changes in PDAI score, disease control, Physician Global Assessment (PGA), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), relapse rate, time to relapse, and corticosteroid-sparing effects.
Translational assessments include peripheral CD19-positive B-cell depletion and reconstitution, B-cell subset dynamics, serum anti-desmoglein 1 and 3 antibody levels, and serum cytokine profiles. CAR-T pharmacokinetics will be evaluated through CAR transgene copy number and circulating CAR-positive T-cell detection, including expansion and persistence metrics.
- Conditions
- Pemphigus Vulgaris
- Being tested
- Autologous CD19 CAR-T cells
- Medical subject headings
- Pemphigus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous CD19 CAR-T cellsBiological
Autologous CD19 CAR-T cells are manufactured ex vivo using the participant's own T cells collected by leukapheresis. The CAR construct targets CD19-expressing B cells and consists of a single-chain variable fragment directed against CD19. Participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide prior to CAR-T cell infusion according to the protocol-defined schedule. Following completion of lymphodepletion, each participant will receive a single intravenous infusion of autologous CD19 CAR-T cells under inpatient monitoring. Premedication, including acetaminophen and diphenhydramine, may be administered prior to infusion at the investigator's discretion in accordance with institutional practice.
| Study group | Role | What they receive |
|---|---|---|
| CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris | Experimental | Participants with moderate-to-severe refractory pemphigus vulgaris will undergo leukapheresis for ex vivo manufacturing of autologous CD19 CAR-T cells. The CAR-T product is individually manufactured from each participant's own peripheral blood mononuclear cells and reinfused into the same participant; therefore, this is an autologous, patient-specific cellular therapy and not an allogeneic or off-the-shelf product. Following confirmation of product release, participants will receive protocol-defined lymphodepleting chemotherapy prior to CAR-T infusion, followed by a single intravenous infusion of autologous CD19 CAR-T cells. Participants will be monitored for safety, pharmacokinetics, pharmacodynamics, immune reconstitution, and preliminary clinical efficacy. Receives: Biological: Autologous CD19 CAR-T cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and Severity of Treatment-Emergent Adverse Events
Treatment-emergent adverse events, serious adverse events, dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections, cytopenias, organ toxicities, infusion-related reactions, and clinically significant laboratory abnormalities will be assessed. Adverse events will be graded according to CTCAE v5.0, and immune effector cell-related toxicities will be assessed according to applicable consensus grading criteria.
Measured: From initiation of lymphodepleting chemotherapy through Day 90 after CAR-T cell infusion
Change From Baseline in PDAI Score at Week 12
The change from baseline in Pemphigus Disease Area Index (PDAI) score at Week 12 will be assessed to evaluate preliminary clinical efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Measured: Baseline and Week 12
Proportion of participants achieving disease control at Week 4 after CAR-T infusion
Disease control is defined as cessation of new active cutaneous or mucosal lesions with established lesion healing or no further progression of existing lesions, as assessed by the investigator. This endpoint evaluates the early clinical response following CD19 CAR-T cell therapy and reflects initial disease stabilization after B-cell depletion.
Measured: Week 4
Secondary outcomes (16)
Change From Baseline in Pemphigus Disease Area Index （PDAI） Score Over Time (Range 0-263)
Changes from baseline in Pemphigus Disease Area Index (PDAI) score will be assessed at scheduled follow-up visits to evaluate the durability of clinical response. The total PDAI score ranges from 0 to 263, with higher scores indicating more severe disease.
Measured: Baseline through Week 96 after CAR-T cell infusion
Change From Baseline in Physician Global Assessment Score (PGA) (Range 0-10)
Change from baseline in PGA score will be assessed at scheduled follow-up visits. PGA is a physician-rated global assessment of pemphigus disease severity, with higher scores indicating more severe disease activity.
Measured: Baseline through Week 96 after CAR-T cell infusion
Change from Baseline in Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) (Range 0-206)
Change from baseline in ABSIS will be assessed at scheduled follow-up visits. ABSIS is used to evaluate autoimmune bullous disease activity, with higher scores indicating more severe disease activity.
Measured: Baseline through Week 96 after CAR-T cell infusion
Proportion of participants achieving disease control at Week 12
Disease control is defined as cessation of new active cutaneous or mucosal lesions with healing or stabilization of existing lesions, as assessed by the investigator. This endpoint evaluates the durability and consolidation of clinical response following CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Measured: Week 12
Change From Baseline in Anti-Desmoglein 1 and Anti-Desmoglein 3 Antibody Levels
Serum anti-desmoglein 1 and anti-desmoglein 3 antibody levels will be measured to evaluate changes in pemphigus-related autoantibody responses after CD19 CAR-T cell therapy.
Measured: Baseline through Week 96 after CAR-T cell infusion
Peripheral CD19-Positive B-Cell Depletion and Reconstitution
Peripheral CD19-positive B-cell counts and B-cell subset dynamics will be assessed to evaluate the pharmacodynamic effect of CD19 CAR-T cell therapy, including B-cell depletion, time to B-cell aplasia, duration of B-cell depletion, and B-cell reconstitution.
Measured: Baseline through Week 96 after CAR-T cell infusion
Number of Circulating CAR-Positive T Cells in Peripheral Blood
The number of circulating CAR-positive T cells in peripheral blood will be measured by flow cytometry at scheduled time points after CAR-T cell infusion to assess in vivo CAR-T cell expansion.
Measured: From CAR-T cell infusion through Week 96
CAR Transgene Copy Number in Peripheral Blood
CAR transgene copy number in peripheral blood will be measured by quantitative polymerase chain reaction or digital PCR at scheduled time points after CAR-T cell infusion to assess CAR-T cell expansion and persistence.
Measured: From CAR-T cell infusion through Week 96
Duration of Detectable CAR-T Cells in Peripheral Blood
The duration of detectable CAR-T cells in peripheral blood will be assessed based on the time from CAR-T cell infusion to the last time point at which CAR-positive T cells or CAR transgene copies remain detectable.
Measured: From CAR-T cell infusion through Week 96
Change From Baseline in Serum Cytokine Levels
Change from baseline in serum cytokine levels will be measured to characterize immune activation after CAR-T cell infusion and to support evaluation of cytokine release syndrome. Cytokines include interleukin-6 (IL-6), interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-10 (IL-10), and interleukin-17A (IL-17A).
Measured: Baseline through Week 96 after CAR-T cell infusion
Change From Baseline in Lymphocyte Subset Counts
Change from baseline in lymphocyte subset counts will be assessed at scheduled follow-up visits by flow cytometry to characterize immune reconstitution after CD19 CAR-T cell therapy. Lymphocyte subsets include CD3-positive T cells, CD4-positive T cells, CD8-positive T cells, CD19-positive B cells, and natural killer cells.
Measured: Baseline through Week 96 after CAR-T cell infusion
Change From Baseline in B-Cell Subset Counts
Change from baseline in B-cell subset counts will be assessed at scheduled follow-up visits by flow cytometry to characterize B-cell depletion and reconstitution after CD19 CAR-T cell therapy. B-cell subsets may include naïve B cells, non-switched memory B cells, switched memory B cells, and plasmablasts.
Measured: Baseline through Week 96 after CAR-T cell infusion
Relapse Rate Through Week 96
Relapse rate will be assessed as the proportion of participants who experience relapse after achieving disease control. Relapse is defined as the occurrence of three or more new lesions within one month that do not heal spontaneously within one week, or extension of established lesions.
Measured: From disease control through Week 96 after CAR-T cell infusion
Time to First Relapse
Time to first relapse will be assessed as the time from achievement of disease control to the first documented relapse.
Measured: From disease control through Week 96 after CAR-T cell infusion
Change From Baseline in Daily Prednisone-Equivalent Corticosteroid Dose
Change from baseline in daily systemic corticosteroid use will be assessed using prednisone-equivalent dose in milligrams per day at scheduled follow-up visits. A lower prednisone-equivalent daily dose indicates reduced corticosteroid requirement after CAR-T cell therapy.
Measured: Baseline through Week 96 after CAR-T cell infusion
Incidence of Serious Adverse Events and Long-Term Safety Events
Serious adverse events, infections, prolonged cytopenias, organ dysfunction, secondary malignancies, and other clinically significant long-term safety events will be recorded throughout the study follow-up period.
Measured: From informed consent through Week 96 after CAR-T cell infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2026
- Study start15 Jan 2026
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pemphigus VulgarisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 3 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jinbo Chen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jinbo Chen, Wuhan Integrated Traditional Chinese and Western Medicine Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07681388
- Sponsor's protocol ID
- WuhanITCWMH-XS-2025139
- Acronym
- RESET-PV-CART
- Status last verified
- Jun 2026
- First submitted
- 19 Jun 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CD19 CAR-T Cell Therapy in Patients With Moderate-to-Severe Refractory Pemphigus Vulgaris
- ClinicalTrials.gov ID
- NCT07681388
- Acronym / sponsor ID
- RESET-PV-CART / WuhanITCWMH-XS-2025139
- Conditions
- Pemphigus Vulgaris
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 3 participants (estimated)
- Lead sponsor
- Jinbo ChenUniversity, hospital or other
- Study start
- 15 Jan 2026 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 2 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Detailed description
This is an investigator-initiated, open-label, single-center, single-arm exploratory interventional study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immune reconstitution, and preliminary clinical efficacy of autologous CD19 CAR-T cell therapy in adult patients with moderate-to-severe refractory pemphigus vulgaris.
Eligible participants are adults with refractory pemphigus vulgaris. After enrollment, participants will undergo leukapheresis for ex vivo manufacturing of autologous CD19 CAR-T cells. After product release, participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide within 2 to 7 days prior to CAR-T infusion.
Participants will receive a single intravenous infusion of autologous CD19 CAR-T cells at a protocol-defined dose (1 X 10^6 CAR-positive T cells per kilogram of body weight). Premedication may be administered at investigator discretion. No comparator group is included.
Participants will be followed for up to 96 weeks after infusion. Safety assessments include monitoring for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections, cytopenias, organ toxicities, and other treatment-emergent adverse events.
Efficacy assessments include changes in PDAI score, disease control, Physician Global Assessment (PGA), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), relapse rate, time to relapse, and corticosteroid-sparing effects.
Translational assessments include peripheral CD19-positive B-cell depletion and reconstitution, B-cell subset dynamics, serum anti-desmoglein 1 and 3 antibody levels, and serum cytokine profiles. CAR-T pharmacokinetics will be evaluated through CAR transgene copy number and circulating CAR-positive T-cell detection, including expansion and persistence metrics.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris | Experimental | Biological: Autologous CD19 CAR-T cellsParticipants with moderate-to-severe refractory pemphigus vulgaris will undergo leukapheresis for ex vivo manufacturing of autologous CD19 CAR-T cells. The CAR-T product is individually manufactured from each participant's own peripheral blood mononuclear cells and reinfused into the same participant; therefore, this is an autologous, patient-specific cellular therapy and not an allogeneic or off-the-shelf product. Following confirmation of product release, participants will receive protocol-defined lymphodepleting chemotherapy prior to CAR-T infusion, followed by a single intravenous infusion of autologous CD19 CAR-T cells. Participants will be monitored for safety, pharmacokinetics, pharmacodynamics, immune reconstitution, and preliminary clinical efficacy. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (21 listed)
- Ability to provide written informed consent.
- Age 18 to 70 years at screening, male or female.
- Diagnosis of pemphigus vulgaris confirmed by clinical presentation, histopathology, direct immunofluorescence (DIF), and positive anti-desmoglein 3 and/or anti-desmoglein 1 antibodies.
- Moderate-to-severe disease activity defined as Pemphigus Disease Area Index (PDAI) ≥ 15 at screening.
- Refractory pemphigus vulgaris is defined as inadequate response, disease relapse, or treatment dependence following systemic corticosteroids and rituximab-based therapy for at least 6 months, with persistent disease activity meeting at least one of the following criteria:
Key exclusion criteria (14 listed)
- Active uncontrolled infection at screening, requiring systemic antimicrobial therapy. Participants with active tuberculosis, hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis infection will be excluded. Participants with hepatitis B surface antigen and/or hepatitis B core antibody positivity may be eligible only if HBV DNA is below the lower limit of quantification and appropriate antiviral prophylaxis is provided at the investigator's discretion.
- History of other active autoimmune disease requiring systemic immunosuppression.
- Previous treatment with any gene-modified cellular therapy, including CAR-T or CAR-NK therapy.
- Prior allogeneic stem cell or solid organ transplantation.
- Severe or uncontrolled cardiovascular, pulmonary, hepatic, or renal disease that would increase risk associated with lymphodepleting chemotherapy or CAR-T cell infusion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous CD19 CAR-T cellsAutologous CD19 CAR-T cells are manufactured ex vivo using the participant's own T cells collected by leukapheresis. The CAR construct targets CD19-expressing B cells and consists of a single-chain variable fragment directed against CD19. Participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide prior to CAR-T cell infusion according to the protocol-defined schedule. Following completion of lymphodepletion, each participant will receive a single intravenous infusion of autologous CD19 CAR-T cells under inpatient monitoring. Premedication, including acetaminophen and diphenhydramine, may be administered prior to infusion at the investigator's discretion in accordance with institutional practice. | Biological | CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris |
Primary outcome
Incidence and Severity of Treatment-Emergent Adverse Events
Time frame: From initiation of lymphodepleting chemotherapy through Day 90 after CAR-T cell infusion
Treatment-emergent adverse events, serious adverse events, dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections, cytopenias, organ toxicities, infusion-related reactions, and clinically significant laboratory abnormalities will be assessed. Adverse events will be graded according to CTCAE v5.0, and immune effector cell-related toxicities will be assessed according to applicable consensus grading criteria.
Change From Baseline in PDAI Score at Week 12
Time frame: Baseline and Week 12
The change from baseline in Pemphigus Disease Area Index (PDAI) score at Week 12 will be assessed to evaluate preliminary clinical efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Proportion of participants achieving disease control at Week 4 after CAR-T infusion
Time frame: Week 4
Disease control is defined as cessation of new active cutaneous or mucosal lesions with established lesion healing or no further progression of existing lesions, as assessed by the investigator. This endpoint evaluates the early clinical response following CD19 CAR-T cell therapy and reflects initial disease stabilization after B-cell depletion.
16 secondary outcomes
Change From Baseline in Pemphigus Disease Area Index （PDAI） Score Over Time (Range 0-263)
Time frame: Baseline through Week 96 after CAR-T cell infusion
Change From Baseline in Physician Global Assessment Score (PGA) (Range 0-10)
Time frame: Baseline through Week 96 after CAR-T cell infusion
Change from Baseline in Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) (Range 0-206)
Time frame: Baseline through Week 96 after CAR-T cell infusion
Proportion of participants achieving disease control at Week 12
Time frame: Week 12
Change From Baseline in Anti-Desmoglein 1 and Anti-Desmoglein 3 Antibody Levels
Time frame: Baseline through Week 96 after CAR-T cell infusion
Peripheral CD19-Positive B-Cell Depletion and Reconstitution
Time frame: Baseline through Week 96 after CAR-T cell infusion
Number of Circulating CAR-Positive T Cells in Peripheral Blood
Time frame: From CAR-T cell infusion through Week 96
CAR Transgene Copy Number in Peripheral Blood
Time frame: From CAR-T cell infusion through Week 96
Duration of Detectable CAR-T Cells in Peripheral Blood
Time frame: From CAR-T cell infusion through Week 96
Change From Baseline in Serum Cytokine Levels
Time frame: Baseline through Week 96 after CAR-T cell infusion
Change From Baseline in Lymphocyte Subset Counts
Time frame: Baseline through Week 96 after CAR-T cell infusion
Change From Baseline in B-Cell Subset Counts
Time frame: Baseline through Week 96 after CAR-T cell infusion
Relapse Rate Through Week 96
Time frame: From disease control through Week 96 after CAR-T cell infusion
Time to First Relapse
Time frame: From disease control through Week 96 after CAR-T cell infusion
Change From Baseline in Daily Prednisone-Equivalent Corticosteroid Dose
Time frame: Baseline through Week 96 after CAR-T cell infusion
Incidence of Serious Adverse Events and Long-Term Safety Events
Time frame: From informed consent through Week 96 after CAR-T cell infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Pemphigus Vulgaris
RecruitingPhase 1/2
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Pemphigus Vulgaris
Not yet recruitingEarly Phase 1
Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris
Pemphigus Vulgaris, Rituximab (RTx)
Recruiting
Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.
Oral Lesions in Patients With Pemphigus Vulgaris
RecruitingObservational study
Autoimmune Blistering Diseases Study
Pemphigus Vulgaris, Pemphigus Foliaceus
Not yet recruiting
Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.
Pemphigus Vulgaris
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiaoya Du contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autologous CD19 CAR-T cells in people with Pemphigus Vulgaris, run by Jinbo Chen at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jinbo Chen, MD, PhD (+86 188 2736 3048, chen999jb@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and Severity of Treatment-Emergent Adverse Events (time frame: From initiation of lymphodepleting chemotherapy through Day 90 after CAR-T cell infusion). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.